Metamizol (Metamizole Sodium)

Metamizole works by non‑selectively inhibiting cyclooxygenase enzymes, which reduces prostaglandin production, and by exerting central analgesic actions that are not fully understood. This combination provides both pain‑relieving and fever‑reducing effects.

The exact dose of Metamizol is determined by the prescribing clinician based on the patient’s condition, age, weight, and response. Healthcare professionals tailor the regimen to achieve optimal pain control or fever reduction while monitoring safety.

Safety data for Metamizol during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the possible risk to the fetus or infant, and only under medical supervision.

To order Metamizol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizol belongs to the pyrazolone class, offering analgesic and antipyretic effects similar to NSAIDs but with a distinct safety profile. Unlike ibuprofen or naproxen, it carries a risk of severe blood‑cell disorders, so clinicians weigh benefits against these specific risks when selecting therapy.

Metamizol tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Metamizol is supplied as oral tablets that are swallowed whole with a glass of water. It is taken by mouth as directed by a healthcare professional, typically with or without food depending on individual tolerance.

The most serious risks include agranulocytosis, aplastic anemia, severe skin reactions such as Stevens‑Johnson syndrome, and anaphylactic shock. Patients should be monitored for signs of infection, unusual bleeding, or skin changes, and treatment should be stopped immediately if these occur.

Metamizol should be avoided in individuals with known hypersensitivity to the drug, a history of blood‑cell disorders, severe renal impairment, or those currently receiving other myelosuppressive therapies. Pregnant or breastfeeding women should use it only if clearly indicated by a physician.